<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01686204</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0669</org_study_id>
    <nct_id>NCT01686204</nct_id>
  </id_info>
  <brief_title>Reduction of Obesity-Associated Intestinal Inflammation by Low-Fat Dairy Yogurt</brief_title>
  <official_title>Reduction of Obesity-Associated Intestinal Inflammation by Low-Fat Dairy Yogurt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dairy Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <brief_summary>
    <textblock>
      The main objective of this work is to conduct a clinical trial in obese and non-obese
      individuals testing the ability of low-fat dairy yogurt to improve gastrointestinal health
      and reduce chronic inflammation. Our central hypothesis is that short and long-term
      consumption of low-fat dairy yogurt will reduce inflammation to a greater extent in obese
      individuals by improving intestinal barrier function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma soluble cluster of differentiation 14 (sCD14)</measure>
    <time_frame>0, 3, 6, and 9 wk</time_frame>
    <description>Fasting plasma sCD14 (change from baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma interleukin-6 (IL-6)</measure>
    <time_frame>0, 3, 6, 9 wk</time_frame>
    <description>Fasting plasma IL-6 (change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial sCD14</measure>
    <time_frame>0 and 9 wk</time_frame>
    <description>Postprandial plasma sCD14 following a high-fat, high-calorie challenge meal (area under curve)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial interleukin-6 (IL-6)</measure>
    <time_frame>0 and 9 wk</time_frame>
    <description>Postprandial plasma IL-6 following a high-fat, high-calorie challenge meal (area under curve)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fasting lipopolysaccharide binding protein (LBP)</measure>
    <time_frame>0 and 9 wk</time_frame>
    <description>Determined by immunoassay</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma endotoxin (LPS, lipopolysaccharide)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined by limulus amebocyte lysate assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma core antibodies to endotoxin</measure>
    <time_frame>0 and 9 wk</time_frame>
    <description>Immunoglobulin M Endotoxin-core antibody (IgM EndoCAb)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma anandamide (AEA)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined by LC-MS</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma 2-arachidonoylglycerol (2-AG)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined by LC-MS</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma IL-10</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined by immunoassay</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma high-sensitivity C-reactive protein (hsCRP)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined in fasting plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma Tumor Necrosis Factor-alpha (TNF-α)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined in fasting plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma Soluble TNF-Receptor II (sTNF-RII)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined in fasting plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF-alpha/sTNF-RII ratio</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined in fasting plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined in fasting plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma triglycerides</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined in fasting plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma insulin</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined in fasting plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma soluble cluster of differentiation 14 (sCD14)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Determined in fasting plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Body weight</measure>
    <time_frame>0, 3, 6, 9 wk</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body mass index</measure>
    <time_frame>0, 3, 6, 9 wk</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Waist circumference</measure>
    <time_frame>0, 3, 6, 9 wk</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>0, 3, 6, 9 wk</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>0, 3, 6, 9 wk</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fasting RPLP0, encoding ribosomal protein large P0</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5)</description>
  </other_outcome>
  <other_outcome>
    <measure>TLR4, encoding Toll-like receptor 4</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5)</description>
  </other_outcome>
  <other_outcome>
    <measure>RELA, encoding p65 subunit of nuclear factor kappa B</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5)</description>
  </other_outcome>
  <other_outcome>
    <measure>NFKBIA, encoding nuclear factor kappa B inhibitor alpha</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5)</description>
  </other_outcome>
  <other_outcome>
    <measure>PTGS2, encoding cyclooxygenase-2 (COX-2)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5)</description>
  </other_outcome>
  <other_outcome>
    <measure>NCF1,encoding the p47 subunit of nicotinamide adenine dinucleotide phosphate-oxidase, (NADPH oxidase)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5)</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF, encoding tumor necrosis factors (TNF)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5)</description>
  </other_outcome>
  <other_outcome>
    <measure>IFNG, encoding interferon-γ</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5)</description>
  </other_outcome>
  <other_outcome>
    <measure>TGFB1, encoding transforming growth factor beta 1 (TGFβ1)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>mRNA expression of peripheral blood mononuclear cell normalized to encoding 18s rRNA (RNA18S5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Postprandial plasma glucose</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Postprandial plasma glucose following a high-fat, high-calorie challenge meal (area under curve)</description>
  </other_outcome>
  <other_outcome>
    <measure>Postprandial plasma triglycerides</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Postprandial plasma triglycerides following a high-fat, high-calorie challenge meal (area under curve)</description>
  </other_outcome>
  <other_outcome>
    <measure>Postprandial lipopolysaccharide binding protein (LBP)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Postprandial plasma LBP following a high-fat, high-calorie challenge meal (area under curve)</description>
  </other_outcome>
  <other_outcome>
    <measure>Postprandial lipopolysaccharide (LPS)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Postprandial plasma LPS following a high-fat, high-calorie challenge meal determined by limulus amebocyte lysate assay (area under curve)</description>
  </other_outcome>
  <other_outcome>
    <measure>Postprandial lipopolysaccharide binding protein (LBP)/soluble cluster of differentiation 14 (sCD14) ratio</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Postprandial LBP/sCD14 ratio following a high-fat, high-calorie challenge meal (area under curve)</description>
  </other_outcome>
  <other_outcome>
    <measure>Postprandial plasma insulin</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Postprandial plasma insulin following a high-fat, high-calorie challenge meal (area under curve)</description>
  </other_outcome>
  <other_outcome>
    <measure>Energy intake (kcal)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported food intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Total fat (g)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Carbohydrate (g)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Total protein (g)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Total fat (%)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Carbohydrate (%)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Total protein (%)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Cholestrol (mg)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Saturated fatty acids (g)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Vitamin D (μg)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Calcium (mg)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Sodium (mg)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Potassium (mg)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Total sugars (g)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <other_outcome>
    <measure>Added sugars (g)</measure>
    <time_frame>0, 9 wk</time_frame>
    <description>Self-reported nutrient intake determined by dietary records</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Intestinal Barrier Function</condition>
  <condition>Chronic Inflammation</condition>
  <arm_group>
    <arm_group_label>Non-obese individuals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily consumption of 12 oz lowfat yogurt or soy pudding for 9 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese individuals</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption of 12 oz of soy pudding or low fat dairy yogurt daily for 9 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low fat dairy yogurt</intervention_name>
    <description>Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks</description>
    <arm_group_label>Non-obese individuals</arm_group_label>
    <arm_group_label>Obese individuals</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Soy pudding</intervention_name>
    <description>Consumption of 12 oz of low fat soy pudding daily for 9 weeks.</description>
    <arm_group_label>Non-obese individuals</arm_group_label>
    <arm_group_label>Obese individuals</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premenopausal women

          -  BMI from 18.5-27 and 30-40 kg/m2

          -  resting blood pressure &lt;140/90 mmHg

          -  not taking medication to control hypertension

          -  stable body weight for the previous 2 months

          -  willing to maintain a normal exercise level and avoid exercise 24 h prior to blood
             sampling

          -  willing to avoid yogurt and probiotic-containing foods or consume 2 servings of yogurt
             for the duration of the study

        Exclusion Criteria:

          -  previous diagnoses of cardiovascular disease (CVD), diabetes, or arthritis (except for
             osteo-arthritis)

          -  currently being treated for cancer (i.e., chemotherapy, radiation therapy)

          -  prescribed estrogen replacement therapy

          -  practicing weight-loss, vegetarian, kosher, or vegan diets

          -  currently taking dietary supplements

          -  exceed alcohol consumption more than moderate drinking (1 drink/day or a total of
             7/week)

          -  actively using antibiotics

          -  taking anti-inflammatory drugs

          -  have allergies to soy, egg or milk

          -  perimenopausal or menopausal symptoms
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley W Bolling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Food Science, Babcock Hall</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2012</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Yogurt</keyword>
  <keyword>Intestine</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Obese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

